Global Metastatic Melanoma Diagnostic Market 2022 by Company, Regions, Type and Application, Forecast to 2028
The Metastatic Melanoma Diagnostic market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Metastatic Melanoma Diagnostic market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Pathology Laboratories accounting for % of the Metastatic Melanoma Diagnostic global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While BRAF Mutation segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Metastatic Melanoma Diagnostic include Myriad Genetics, Abbott Laboratories, Foundation Medicine, Pathway Genomics Corporation, and Cancer Genetics, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Metastatic Melanoma Diagnostic market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Chapter 1, to describe Metastatic Melanoma Diagnostic product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Metastatic Melanoma Diagnostic, with revenue, gross margin and global market share of Metastatic Melanoma Diagnostic from 2019 to 2022.
Chapter 3, the Metastatic Melanoma Diagnostic competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Metastatic Melanoma Diagnostic market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Metastatic Melanoma Diagnostic research findings and conclusion, appendix and data source.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Metastatic Melanoma Diagnostic market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Pathology Laboratories accounting for % of the Metastatic Melanoma Diagnostic global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While BRAF Mutation segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Metastatic Melanoma Diagnostic include Myriad Genetics, Abbott Laboratories, Foundation Medicine, Pathway Genomics Corporation, and Cancer Genetics, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Metastatic Melanoma Diagnostic market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
- BRAF Mutation
- Circulating Tumor Cells (CTCs)
- Immunohistochemistry
- Others
- Pathology Laboratories
- Hospitals
- Cancer Research Centres
- Others
- Myriad Genetics
- Abbott Laboratories
- Foundation Medicine
- Pathway Genomics Corporation
- Cancer Genetics
- Castle Biosciences
- NeoGenomics
- Dermtech
- Sysmex Inostics
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
- South America (Brazil, Argentina, Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter 1, to describe Metastatic Melanoma Diagnostic product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Metastatic Melanoma Diagnostic, with revenue, gross margin and global market share of Metastatic Melanoma Diagnostic from 2019 to 2022.
Chapter 3, the Metastatic Melanoma Diagnostic competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Metastatic Melanoma Diagnostic market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Metastatic Melanoma Diagnostic research findings and conclusion, appendix and data source.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Metastatic Melanoma Diagnostic
1.2 Classification of Metastatic Melanoma Diagnostic by Type
1.2.1 Overview: Global Metastatic Melanoma Diagnostic Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Metastatic Melanoma Diagnostic Revenue Market Share by Type in 2021
1.2.3 BRAF Mutation
1.2.4 Circulating Tumor Cells (CTCs)
1.2.5 Immunohistochemistry
1.2.6 Others
1.3 Global Metastatic Melanoma Diagnostic Market by Application
1.3.1 Overview: Global Metastatic Melanoma Diagnostic Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Pathology Laboratories
1.3.3 Hospitals
1.3.4 Cancer Research Centres
1.3.5 Others
1.4 Global Metastatic Melanoma Diagnostic Market Size & Forecast
1.5 Global Metastatic Melanoma Diagnostic Market Size and Forecast by Region
1.5.1 Global Metastatic Melanoma Diagnostic Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Metastatic Melanoma Diagnostic Market Size by Region, (2017-2022)
1.5.3 North America Metastatic Melanoma Diagnostic Market Size and Prospect (2017-2028)
1.5.4 Europe Metastatic Melanoma Diagnostic Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Metastatic Melanoma Diagnostic Market Size and Prospect (2017-2028)
1.5.6 South America Metastatic Melanoma Diagnostic Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Metastatic Melanoma Diagnostic Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Metastatic Melanoma Diagnostic Market Drivers
1.6.2 Metastatic Melanoma Diagnostic Market Restraints
1.6.3 Metastatic Melanoma Diagnostic Trends Analysis
2 COMPANY PROFILES
2.1 Myriad Genetics
2.1.1 Myriad Genetics Details
2.1.2 Myriad Genetics Major Business
2.1.3 Myriad Genetics Metastatic Melanoma Diagnostic Product and Solutions
2.1.4 Myriad Genetics Metastatic Melanoma Diagnostic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Myriad Genetics Recent Developments and Future Plans
2.2 Abbott Laboratories
2.2.1 Abbott Laboratories Details
2.2.2 Abbott Laboratories Major Business
2.2.3 Abbott Laboratories Metastatic Melanoma Diagnostic Product and Solutions
2.2.4 Abbott Laboratories Metastatic Melanoma Diagnostic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Abbott Laboratories Recent Developments and Future Plans
2.3 Foundation Medicine
2.3.1 Foundation Medicine Details
2.3.2 Foundation Medicine Major Business
2.3.3 Foundation Medicine Metastatic Melanoma Diagnostic Product and Solutions
2.3.4 Foundation Medicine Metastatic Melanoma Diagnostic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Foundation Medicine Recent Developments and Future Plans
2.4 Pathway Genomics Corporation
2.4.1 Pathway Genomics Corporation Details
2.4.2 Pathway Genomics Corporation Major Business
2.4.3 Pathway Genomics Corporation Metastatic Melanoma Diagnostic Product and Solutions
2.4.4 Pathway Genomics Corporation Metastatic Melanoma Diagnostic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Pathway Genomics Corporation Recent Developments and Future Plans
2.5 Cancer Genetics
2.5.1 Cancer Genetics Details
2.5.2 Cancer Genetics Major Business
2.5.3 Cancer Genetics Metastatic Melanoma Diagnostic Product and Solutions
2.5.4 Cancer Genetics Metastatic Melanoma Diagnostic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Cancer Genetics Recent Developments and Future Plans
2.6 Castle Biosciences
2.6.1 Castle Biosciences Details
2.6.2 Castle Biosciences Major Business
2.6.3 Castle Biosciences Metastatic Melanoma Diagnostic Product and Solutions
2.6.4 Castle Biosciences Metastatic Melanoma Diagnostic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Castle Biosciences Recent Developments and Future Plans
2.7 NeoGenomics
2.7.1 NeoGenomics Details
2.7.2 NeoGenomics Major Business
2.7.3 NeoGenomics Metastatic Melanoma Diagnostic Product and Solutions
2.7.4 NeoGenomics Metastatic Melanoma Diagnostic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 NeoGenomics Recent Developments and Future Plans
2.8 Dermtech
2.8.1 Dermtech Details
2.8.2 Dermtech Major Business
2.8.3 Dermtech Metastatic Melanoma Diagnostic Product and Solutions
2.8.4 Dermtech Metastatic Melanoma Diagnostic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Dermtech Recent Developments and Future Plans
2.9 Sysmex Inostics
2.9.1 Sysmex Inostics Details
2.9.2 Sysmex Inostics Major Business
2.9.3 Sysmex Inostics Metastatic Melanoma Diagnostic Product and Solutions
2.9.4 Sysmex Inostics Metastatic Melanoma Diagnostic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Sysmex Inostics Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Metastatic Melanoma Diagnostic Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Metastatic Melanoma Diagnostic Players Market Share in 2021
3.2.2 Top 10 Metastatic Melanoma Diagnostic Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Metastatic Melanoma Diagnostic Players Head Office, Products and Services Provided
3.4 Metastatic Melanoma Diagnostic Mergers & Acquisitions
3.5 Metastatic Melanoma Diagnostic New Entrants and Expansion Plans
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Metastatic Melanoma Diagnostic Revenue and Market Share by Type (2017-2022)
4.2 Global Metastatic Melanoma Diagnostic Market Forecast by Type (2023-2028)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Metastatic Melanoma Diagnostic Revenue Market Share by Application (2017-2022)
5.2 Global Metastatic Melanoma Diagnostic Market Forecast by Application (2023-2028)
6 NORTH AMERICA BY COUNTRY, BY TYPE, AND BY APPLICATION
6.1 North America Metastatic Melanoma Diagnostic Revenue by Type (2017-2028)
6.2 North America Metastatic Melanoma Diagnostic Revenue by Application (2017-2028)
6.3 North America Metastatic Melanoma Diagnostic Market Size by Country
6.3.1 North America Metastatic Melanoma Diagnostic Revenue by Country (2017-2028)
6.3.2 United States Metastatic Melanoma Diagnostic Market Size and Forecast (2017-2028)
6.3.3 Canada Metastatic Melanoma Diagnostic Market Size and Forecast (2017-2028)
6.3.4 Mexico Metastatic Melanoma Diagnostic Market Size and Forecast (2017-2028)
7 EUROPE BY COUNTRY, BY TYPE, AND BY APPLICATION
7.1 Europe Metastatic Melanoma Diagnostic Revenue by Type (2017-2028)
7.2 Europe Metastatic Melanoma Diagnostic Revenue by Application (2017-2028)
7.3 Europe Metastatic Melanoma Diagnostic Market Size by Country
7.3.1 Europe Metastatic Melanoma Diagnostic Revenue by Country (2017-2028)
7.3.2 Germany Metastatic Melanoma Diagnostic Market Size and Forecast (2017-2028)
7.3.3 France Metastatic Melanoma Diagnostic Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Metastatic Melanoma Diagnostic Market Size and Forecast (2017-2028)
7.3.5 Russia Metastatic Melanoma Diagnostic Market Size and Forecast (2017-2028)
7.3.6 Italy Metastatic Melanoma Diagnostic Market Size and Forecast (2017-2028)
8 ASIA-PACIFIC BY REGION, BY TYPE, AND BY APPLICATION
8.1 Asia-Pacific Metastatic Melanoma Diagnostic Revenue by Type (2017-2028)
8.2 Asia-Pacific Metastatic Melanoma Diagnostic Revenue by Application (2017-2028)
8.3 Asia-Pacific Metastatic Melanoma Diagnostic Market Size by Region
8.3.1 Asia-Pacific Metastatic Melanoma Diagnostic Revenue by Region (2017-2028)
8.3.2 China Metastatic Melanoma Diagnostic Market Size and Forecast (2017-2028)
8.3.3 Japan Metastatic Melanoma Diagnostic Market Size and Forecast (2017-2028)
8.3.4 South Korea Metastatic Melanoma Diagnostic Market Size and Forecast (2017-2028)
8.3.5 India Metastatic Melanoma Diagnostic Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Metastatic Melanoma Diagnostic Market Size and Forecast (2017-2028)
8.3.7 Australia Metastatic Melanoma Diagnostic Market Size and Forecast (2017-2028)
9 SOUTH AMERICA BY COUNTRY, BY TYPE, AND BY APPLICATION
9.1 South America Metastatic Melanoma Diagnostic Revenue by Type (2017-2028)
9.2 South America Metastatic Melanoma Diagnostic Revenue by Application (2017-2028)
9.3 South America Metastatic Melanoma Diagnostic Market Size by Country
9.3.1 South America Metastatic Melanoma Diagnostic Revenue by Country (2017-2028)
9.3.2 Brazil Metastatic Melanoma Diagnostic Market Size and Forecast (2017-2028)
9.3.3 Argentina Metastatic Melanoma Diagnostic Market Size and Forecast (2017-2028)
10 MIDDLE EAST & AFRICA BY COUNTRY, BY TYPE, AND BY APPLICATION
10.1 Middle East & Africa Metastatic Melanoma Diagnostic Revenue by Type (2017-2028)
10.2 Middle East & Africa Metastatic Melanoma Diagnostic Revenue by Application (2017-2028)
10.3 Middle East & Africa Metastatic Melanoma Diagnostic Market Size by Country
10.3.1 Middle East & Africa Metastatic Melanoma Diagnostic Revenue by Country (2017-2028)
10.3.2 Turkey Metastatic Melanoma Diagnostic Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Metastatic Melanoma Diagnostic Market Size and Forecast (2017-2028)
10.3.4 UAE Metastatic Melanoma Diagnostic Market Size and Forecast (2017-2028)
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Product Overview and Scope of Metastatic Melanoma Diagnostic
1.2 Classification of Metastatic Melanoma Diagnostic by Type
1.2.1 Overview: Global Metastatic Melanoma Diagnostic Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Metastatic Melanoma Diagnostic Revenue Market Share by Type in 2021
1.2.3 BRAF Mutation
1.2.4 Circulating Tumor Cells (CTCs)
1.2.5 Immunohistochemistry
1.2.6 Others
1.3 Global Metastatic Melanoma Diagnostic Market by Application
1.3.1 Overview: Global Metastatic Melanoma Diagnostic Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Pathology Laboratories
1.3.3 Hospitals
1.3.4 Cancer Research Centres
1.3.5 Others
1.4 Global Metastatic Melanoma Diagnostic Market Size & Forecast
1.5 Global Metastatic Melanoma Diagnostic Market Size and Forecast by Region
1.5.1 Global Metastatic Melanoma Diagnostic Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Metastatic Melanoma Diagnostic Market Size by Region, (2017-2022)
1.5.3 North America Metastatic Melanoma Diagnostic Market Size and Prospect (2017-2028)
1.5.4 Europe Metastatic Melanoma Diagnostic Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Metastatic Melanoma Diagnostic Market Size and Prospect (2017-2028)
1.5.6 South America Metastatic Melanoma Diagnostic Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Metastatic Melanoma Diagnostic Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Metastatic Melanoma Diagnostic Market Drivers
1.6.2 Metastatic Melanoma Diagnostic Market Restraints
1.6.3 Metastatic Melanoma Diagnostic Trends Analysis
2 COMPANY PROFILES
2.1 Myriad Genetics
2.1.1 Myriad Genetics Details
2.1.2 Myriad Genetics Major Business
2.1.3 Myriad Genetics Metastatic Melanoma Diagnostic Product and Solutions
2.1.4 Myriad Genetics Metastatic Melanoma Diagnostic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Myriad Genetics Recent Developments and Future Plans
2.2 Abbott Laboratories
2.2.1 Abbott Laboratories Details
2.2.2 Abbott Laboratories Major Business
2.2.3 Abbott Laboratories Metastatic Melanoma Diagnostic Product and Solutions
2.2.4 Abbott Laboratories Metastatic Melanoma Diagnostic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Abbott Laboratories Recent Developments and Future Plans
2.3 Foundation Medicine
2.3.1 Foundation Medicine Details
2.3.2 Foundation Medicine Major Business
2.3.3 Foundation Medicine Metastatic Melanoma Diagnostic Product and Solutions
2.3.4 Foundation Medicine Metastatic Melanoma Diagnostic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Foundation Medicine Recent Developments and Future Plans
2.4 Pathway Genomics Corporation
2.4.1 Pathway Genomics Corporation Details
2.4.2 Pathway Genomics Corporation Major Business
2.4.3 Pathway Genomics Corporation Metastatic Melanoma Diagnostic Product and Solutions
2.4.4 Pathway Genomics Corporation Metastatic Melanoma Diagnostic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Pathway Genomics Corporation Recent Developments and Future Plans
2.5 Cancer Genetics
2.5.1 Cancer Genetics Details
2.5.2 Cancer Genetics Major Business
2.5.3 Cancer Genetics Metastatic Melanoma Diagnostic Product and Solutions
2.5.4 Cancer Genetics Metastatic Melanoma Diagnostic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Cancer Genetics Recent Developments and Future Plans
2.6 Castle Biosciences
2.6.1 Castle Biosciences Details
2.6.2 Castle Biosciences Major Business
2.6.3 Castle Biosciences Metastatic Melanoma Diagnostic Product and Solutions
2.6.4 Castle Biosciences Metastatic Melanoma Diagnostic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Castle Biosciences Recent Developments and Future Plans
2.7 NeoGenomics
2.7.1 NeoGenomics Details
2.7.2 NeoGenomics Major Business
2.7.3 NeoGenomics Metastatic Melanoma Diagnostic Product and Solutions
2.7.4 NeoGenomics Metastatic Melanoma Diagnostic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 NeoGenomics Recent Developments and Future Plans
2.8 Dermtech
2.8.1 Dermtech Details
2.8.2 Dermtech Major Business
2.8.3 Dermtech Metastatic Melanoma Diagnostic Product and Solutions
2.8.4 Dermtech Metastatic Melanoma Diagnostic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Dermtech Recent Developments and Future Plans
2.9 Sysmex Inostics
2.9.1 Sysmex Inostics Details
2.9.2 Sysmex Inostics Major Business
2.9.3 Sysmex Inostics Metastatic Melanoma Diagnostic Product and Solutions
2.9.4 Sysmex Inostics Metastatic Melanoma Diagnostic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Sysmex Inostics Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Metastatic Melanoma Diagnostic Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Metastatic Melanoma Diagnostic Players Market Share in 2021
3.2.2 Top 10 Metastatic Melanoma Diagnostic Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Metastatic Melanoma Diagnostic Players Head Office, Products and Services Provided
3.4 Metastatic Melanoma Diagnostic Mergers & Acquisitions
3.5 Metastatic Melanoma Diagnostic New Entrants and Expansion Plans
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Metastatic Melanoma Diagnostic Revenue and Market Share by Type (2017-2022)
4.2 Global Metastatic Melanoma Diagnostic Market Forecast by Type (2023-2028)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Metastatic Melanoma Diagnostic Revenue Market Share by Application (2017-2022)
5.2 Global Metastatic Melanoma Diagnostic Market Forecast by Application (2023-2028)
6 NORTH AMERICA BY COUNTRY, BY TYPE, AND BY APPLICATION
6.1 North America Metastatic Melanoma Diagnostic Revenue by Type (2017-2028)
6.2 North America Metastatic Melanoma Diagnostic Revenue by Application (2017-2028)
6.3 North America Metastatic Melanoma Diagnostic Market Size by Country
6.3.1 North America Metastatic Melanoma Diagnostic Revenue by Country (2017-2028)
6.3.2 United States Metastatic Melanoma Diagnostic Market Size and Forecast (2017-2028)
6.3.3 Canada Metastatic Melanoma Diagnostic Market Size and Forecast (2017-2028)
6.3.4 Mexico Metastatic Melanoma Diagnostic Market Size and Forecast (2017-2028)
7 EUROPE BY COUNTRY, BY TYPE, AND BY APPLICATION
7.1 Europe Metastatic Melanoma Diagnostic Revenue by Type (2017-2028)
7.2 Europe Metastatic Melanoma Diagnostic Revenue by Application (2017-2028)
7.3 Europe Metastatic Melanoma Diagnostic Market Size by Country
7.3.1 Europe Metastatic Melanoma Diagnostic Revenue by Country (2017-2028)
7.3.2 Germany Metastatic Melanoma Diagnostic Market Size and Forecast (2017-2028)
7.3.3 France Metastatic Melanoma Diagnostic Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Metastatic Melanoma Diagnostic Market Size and Forecast (2017-2028)
7.3.5 Russia Metastatic Melanoma Diagnostic Market Size and Forecast (2017-2028)
7.3.6 Italy Metastatic Melanoma Diagnostic Market Size and Forecast (2017-2028)
8 ASIA-PACIFIC BY REGION, BY TYPE, AND BY APPLICATION
8.1 Asia-Pacific Metastatic Melanoma Diagnostic Revenue by Type (2017-2028)
8.2 Asia-Pacific Metastatic Melanoma Diagnostic Revenue by Application (2017-2028)
8.3 Asia-Pacific Metastatic Melanoma Diagnostic Market Size by Region
8.3.1 Asia-Pacific Metastatic Melanoma Diagnostic Revenue by Region (2017-2028)
8.3.2 China Metastatic Melanoma Diagnostic Market Size and Forecast (2017-2028)
8.3.3 Japan Metastatic Melanoma Diagnostic Market Size and Forecast (2017-2028)
8.3.4 South Korea Metastatic Melanoma Diagnostic Market Size and Forecast (2017-2028)
8.3.5 India Metastatic Melanoma Diagnostic Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Metastatic Melanoma Diagnostic Market Size and Forecast (2017-2028)
8.3.7 Australia Metastatic Melanoma Diagnostic Market Size and Forecast (2017-2028)
9 SOUTH AMERICA BY COUNTRY, BY TYPE, AND BY APPLICATION
9.1 South America Metastatic Melanoma Diagnostic Revenue by Type (2017-2028)
9.2 South America Metastatic Melanoma Diagnostic Revenue by Application (2017-2028)
9.3 South America Metastatic Melanoma Diagnostic Market Size by Country
9.3.1 South America Metastatic Melanoma Diagnostic Revenue by Country (2017-2028)
9.3.2 Brazil Metastatic Melanoma Diagnostic Market Size and Forecast (2017-2028)
9.3.3 Argentina Metastatic Melanoma Diagnostic Market Size and Forecast (2017-2028)
10 MIDDLE EAST & AFRICA BY COUNTRY, BY TYPE, AND BY APPLICATION
10.1 Middle East & Africa Metastatic Melanoma Diagnostic Revenue by Type (2017-2028)
10.2 Middle East & Africa Metastatic Melanoma Diagnostic Revenue by Application (2017-2028)
10.3 Middle East & Africa Metastatic Melanoma Diagnostic Market Size by Country
10.3.1 Middle East & Africa Metastatic Melanoma Diagnostic Revenue by Country (2017-2028)
10.3.2 Turkey Metastatic Melanoma Diagnostic Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Metastatic Melanoma Diagnostic Market Size and Forecast (2017-2028)
10.3.4 UAE Metastatic Melanoma Diagnostic Market Size and Forecast (2017-2028)
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. Global Metastatic Melanoma Diagnostic Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Metastatic Melanoma Diagnostic Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Metastatic Melanoma Diagnostic Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Metastatic Melanoma Diagnostic Revenue (USD Million) by Region (2017-2022)
Table 5. Global Metastatic Melanoma Diagnostic Revenue Market Share by Region (2023-2028)
Table 6. Myriad Genetics Corporate Information, Head Office, and Major Competitors
Table 7. Myriad Genetics Major Business
Table 8. Myriad Genetics Metastatic Melanoma Diagnostic Product and Solutions
Table 9. Myriad Genetics Metastatic Melanoma Diagnostic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Abbott Laboratories Corporate Information, Head Office, and Major Competitors
Table 11. Abbott Laboratories Major Business
Table 12. Abbott Laboratories Metastatic Melanoma Diagnostic Product and Solutions
Table 13. Abbott Laboratories Metastatic Melanoma Diagnostic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Foundation Medicine Corporate Information, Head Office, and Major Competitors
Table 15. Foundation Medicine Major Business
Table 16. Foundation Medicine Metastatic Melanoma Diagnostic Product and Solutions
Table 17. Foundation Medicine Metastatic Melanoma Diagnostic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Pathway Genomics Corporation Corporate Information, Head Office, and Major Competitors
Table 19. Pathway Genomics Corporation Major Business
Table 20. Pathway Genomics Corporation Metastatic Melanoma Diagnostic Product and Solutions
Table 21. Pathway Genomics Corporation Metastatic Melanoma Diagnostic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Cancer Genetics Corporate Information, Head Office, and Major Competitors
Table 23. Cancer Genetics Major Business
Table 24. Cancer Genetics Metastatic Melanoma Diagnostic Product and Solutions
Table 25. Cancer Genetics Metastatic Melanoma Diagnostic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Castle Biosciences Corporate Information, Head Office, and Major Competitors
Table 27. Castle Biosciences Major Business
Table 28. Castle Biosciences Metastatic Melanoma Diagnostic Product and Solutions
Table 29. Castle Biosciences Metastatic Melanoma Diagnostic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. NeoGenomics Corporate Information, Head Office, and Major Competitors
Table 31. NeoGenomics Major Business
Table 32. NeoGenomics Metastatic Melanoma Diagnostic Product and Solutions
Table 33. NeoGenomics Metastatic Melanoma Diagnostic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Dermtech Corporate Information, Head Office, and Major Competitors
Table 35. Dermtech Major Business
Table 36. Dermtech Metastatic Melanoma Diagnostic Product and Solutions
Table 37. Dermtech Metastatic Melanoma Diagnostic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Sysmex Inostics Corporate Information, Head Office, and Major Competitors
Table 39. Sysmex Inostics Major Business
Table 40. Sysmex Inostics Metastatic Melanoma Diagnostic Product and Solutions
Table 41. Sysmex Inostics Metastatic Melanoma Diagnostic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Global Metastatic Melanoma Diagnostic Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 43. Global Metastatic Melanoma Diagnostic Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 44. Breakdown of Metastatic Melanoma Diagnostic by Company Type (Tier 1, Tier 2 and Tier 3)
Table 45. Metastatic Melanoma Diagnostic Players Head Office, Products and Services Provided
Table 46. Metastatic Melanoma Diagnostic Mergers & Acquisitions in the Past Five Years
Table 47. Metastatic Melanoma Diagnostic New Entrants and Expansion Plans
Table 48. Global Metastatic Melanoma Diagnostic Revenue (USD Million) by Type (2017-2022)
Table 49. Global Metastatic Melanoma Diagnostic Revenue Share by Type (2017-2022)
Table 50. Global Metastatic Melanoma Diagnostic Revenue Forecast by Type (2023-2028)
Table 51. Global Metastatic Melanoma Diagnostic Revenue by Application (2017-2022)
Table 52. Global Metastatic Melanoma Diagnostic Revenue Forecast by Application (2023-2028)
Table 53. North America Metastatic Melanoma Diagnostic Revenue by Type (2017-2022) & (USD Million)
Table 54. North America Metastatic Melanoma Diagnostic Revenue by Type (2023-2028) & (USD Million)
Table 55. North America Metastatic Melanoma Diagnostic Revenue by Application (2017-2022) & (USD Million)
Table 56. North America Metastatic Melanoma Diagnostic Revenue by Application (2023-2028) & (USD Million)
Table 57. North America Metastatic Melanoma Diagnostic Revenue by Country (2017-2022) & (USD Million)
Table 58. North America Metastatic Melanoma Diagnostic Revenue by Country (2023-2028) & (USD Million)
Table 59. Europe Metastatic Melanoma Diagnostic Revenue by Type (2017-2022) & (USD Million)
Table 60. Europe Metastatic Melanoma Diagnostic Revenue by Type (2023-2028) & (USD Million)
Table 61. Europe Metastatic Melanoma Diagnostic Revenue by Application (2017-2022) & (USD Million)
Table 62. Europe Metastatic Melanoma Diagnostic Revenue by Application (2023-2028) & (USD Million)
Table 63. Europe Metastatic Melanoma Diagnostic Revenue by Country (2017-2022) & (USD Million)
Table 64. Europe Metastatic Melanoma Diagnostic Revenue by Country (2023-2028) & (USD Million)
Table 65. Asia-Pacific Metastatic Melanoma Diagnostic Revenue by Type (2017-2022) & (USD Million)
Table 66. Asia-Pacific Metastatic Melanoma Diagnostic Revenue by Type (2023-2028) & (USD Million)
Table 67. Asia-Pacific Metastatic Melanoma Diagnostic Revenue by Application (2017-2022) & (USD Million)
Table 68. Asia-Pacific Metastatic Melanoma Diagnostic Revenue by Application (2023-2028) & (USD Million)
Table 69. Asia-Pacific Metastatic Melanoma Diagnostic Revenue by Region (2017-2022) & (USD Million)
Table 70. Asia-Pacific Metastatic Melanoma Diagnostic Revenue by Region (2023-2028) & (USD Million)
Table 71. South America Metastatic Melanoma Diagnostic Revenue by Type (2017-2022) & (USD Million)
Table 72. South America Metastatic Melanoma Diagnostic Revenue by Type (2023-2028) & (USD Million)
Table 73. South America Metastatic Melanoma Diagnostic Revenue by Application (2017-2022) & (USD Million)
Table 74. South America Metastatic Melanoma Diagnostic Revenue by Application (2023-2028) & (USD Million)
Table 75. South America Metastatic Melanoma Diagnostic Revenue by Country (2017-2022) & (USD Million)
Table 76. South America Metastatic Melanoma Diagnostic Revenue by Country (2023-2028) & (USD Million)
Table 77. Middle East & Africa Metastatic Melanoma Diagnostic Revenue by Type (2017-2022) & (USD Million)
Table 78. Middle East & Africa Metastatic Melanoma Diagnostic Revenue by Type (2023-2028) & (USD Million)
Table 79. Middle East & Africa Metastatic Melanoma Diagnostic Revenue by Application (2017-2022) & (USD Million)
Table 80. Middle East & Africa Metastatic Melanoma Diagnostic Revenue by Application (2023-2028) & (USD Million)
Table 81. Middle East & Africa Metastatic Melanoma Diagnostic Revenue by Country (2017-2022) & (USD Million)
Table 82. Middle East & Africa Metastatic Melanoma Diagnostic Revenue by Country (2023-2028) & (USD Million)
Table 1. Global Metastatic Melanoma Diagnostic Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Metastatic Melanoma Diagnostic Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Metastatic Melanoma Diagnostic Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Metastatic Melanoma Diagnostic Revenue (USD Million) by Region (2017-2022)
Table 5. Global Metastatic Melanoma Diagnostic Revenue Market Share by Region (2023-2028)
Table 6. Myriad Genetics Corporate Information, Head Office, and Major Competitors
Table 7. Myriad Genetics Major Business
Table 8. Myriad Genetics Metastatic Melanoma Diagnostic Product and Solutions
Table 9. Myriad Genetics Metastatic Melanoma Diagnostic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Abbott Laboratories Corporate Information, Head Office, and Major Competitors
Table 11. Abbott Laboratories Major Business
Table 12. Abbott Laboratories Metastatic Melanoma Diagnostic Product and Solutions
Table 13. Abbott Laboratories Metastatic Melanoma Diagnostic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Foundation Medicine Corporate Information, Head Office, and Major Competitors
Table 15. Foundation Medicine Major Business
Table 16. Foundation Medicine Metastatic Melanoma Diagnostic Product and Solutions
Table 17. Foundation Medicine Metastatic Melanoma Diagnostic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Pathway Genomics Corporation Corporate Information, Head Office, and Major Competitors
Table 19. Pathway Genomics Corporation Major Business
Table 20. Pathway Genomics Corporation Metastatic Melanoma Diagnostic Product and Solutions
Table 21. Pathway Genomics Corporation Metastatic Melanoma Diagnostic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Cancer Genetics Corporate Information, Head Office, and Major Competitors
Table 23. Cancer Genetics Major Business
Table 24. Cancer Genetics Metastatic Melanoma Diagnostic Product and Solutions
Table 25. Cancer Genetics Metastatic Melanoma Diagnostic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Castle Biosciences Corporate Information, Head Office, and Major Competitors
Table 27. Castle Biosciences Major Business
Table 28. Castle Biosciences Metastatic Melanoma Diagnostic Product and Solutions
Table 29. Castle Biosciences Metastatic Melanoma Diagnostic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. NeoGenomics Corporate Information, Head Office, and Major Competitors
Table 31. NeoGenomics Major Business
Table 32. NeoGenomics Metastatic Melanoma Diagnostic Product and Solutions
Table 33. NeoGenomics Metastatic Melanoma Diagnostic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Dermtech Corporate Information, Head Office, and Major Competitors
Table 35. Dermtech Major Business
Table 36. Dermtech Metastatic Melanoma Diagnostic Product and Solutions
Table 37. Dermtech Metastatic Melanoma Diagnostic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Sysmex Inostics Corporate Information, Head Office, and Major Competitors
Table 39. Sysmex Inostics Major Business
Table 40. Sysmex Inostics Metastatic Melanoma Diagnostic Product and Solutions
Table 41. Sysmex Inostics Metastatic Melanoma Diagnostic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Global Metastatic Melanoma Diagnostic Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 43. Global Metastatic Melanoma Diagnostic Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 44. Breakdown of Metastatic Melanoma Diagnostic by Company Type (Tier 1, Tier 2 and Tier 3)
Table 45. Metastatic Melanoma Diagnostic Players Head Office, Products and Services Provided
Table 46. Metastatic Melanoma Diagnostic Mergers & Acquisitions in the Past Five Years
Table 47. Metastatic Melanoma Diagnostic New Entrants and Expansion Plans
Table 48. Global Metastatic Melanoma Diagnostic Revenue (USD Million) by Type (2017-2022)
Table 49. Global Metastatic Melanoma Diagnostic Revenue Share by Type (2017-2022)
Table 50. Global Metastatic Melanoma Diagnostic Revenue Forecast by Type (2023-2028)
Table 51. Global Metastatic Melanoma Diagnostic Revenue by Application (2017-2022)
Table 52. Global Metastatic Melanoma Diagnostic Revenue Forecast by Application (2023-2028)
Table 53. North America Metastatic Melanoma Diagnostic Revenue by Type (2017-2022) & (USD Million)
Table 54. North America Metastatic Melanoma Diagnostic Revenue by Type (2023-2028) & (USD Million)
Table 55. North America Metastatic Melanoma Diagnostic Revenue by Application (2017-2022) & (USD Million)
Table 56. North America Metastatic Melanoma Diagnostic Revenue by Application (2023-2028) & (USD Million)
Table 57. North America Metastatic Melanoma Diagnostic Revenue by Country (2017-2022) & (USD Million)
Table 58. North America Metastatic Melanoma Diagnostic Revenue by Country (2023-2028) & (USD Million)
Table 59. Europe Metastatic Melanoma Diagnostic Revenue by Type (2017-2022) & (USD Million)
Table 60. Europe Metastatic Melanoma Diagnostic Revenue by Type (2023-2028) & (USD Million)
Table 61. Europe Metastatic Melanoma Diagnostic Revenue by Application (2017-2022) & (USD Million)
Table 62. Europe Metastatic Melanoma Diagnostic Revenue by Application (2023-2028) & (USD Million)
Table 63. Europe Metastatic Melanoma Diagnostic Revenue by Country (2017-2022) & (USD Million)
Table 64. Europe Metastatic Melanoma Diagnostic Revenue by Country (2023-2028) & (USD Million)
Table 65. Asia-Pacific Metastatic Melanoma Diagnostic Revenue by Type (2017-2022) & (USD Million)
Table 66. Asia-Pacific Metastatic Melanoma Diagnostic Revenue by Type (2023-2028) & (USD Million)
Table 67. Asia-Pacific Metastatic Melanoma Diagnostic Revenue by Application (2017-2022) & (USD Million)
Table 68. Asia-Pacific Metastatic Melanoma Diagnostic Revenue by Application (2023-2028) & (USD Million)
Table 69. Asia-Pacific Metastatic Melanoma Diagnostic Revenue by Region (2017-2022) & (USD Million)
Table 70. Asia-Pacific Metastatic Melanoma Diagnostic Revenue by Region (2023-2028) & (USD Million)
Table 71. South America Metastatic Melanoma Diagnostic Revenue by Type (2017-2022) & (USD Million)
Table 72. South America Metastatic Melanoma Diagnostic Revenue by Type (2023-2028) & (USD Million)
Table 73. South America Metastatic Melanoma Diagnostic Revenue by Application (2017-2022) & (USD Million)
Table 74. South America Metastatic Melanoma Diagnostic Revenue by Application (2023-2028) & (USD Million)
Table 75. South America Metastatic Melanoma Diagnostic Revenue by Country (2017-2022) & (USD Million)
Table 76. South America Metastatic Melanoma Diagnostic Revenue by Country (2023-2028) & (USD Million)
Table 77. Middle East & Africa Metastatic Melanoma Diagnostic Revenue by Type (2017-2022) & (USD Million)
Table 78. Middle East & Africa Metastatic Melanoma Diagnostic Revenue by Type (2023-2028) & (USD Million)
Table 79. Middle East & Africa Metastatic Melanoma Diagnostic Revenue by Application (2017-2022) & (USD Million)
Table 80. Middle East & Africa Metastatic Melanoma Diagnostic Revenue by Application (2023-2028) & (USD Million)
Table 81. Middle East & Africa Metastatic Melanoma Diagnostic Revenue by Country (2017-2022) & (USD Million)
Table 82. Middle East & Africa Metastatic Melanoma Diagnostic Revenue by Country (2023-2028) & (USD Million)
LIST OF FIGURES
Figure 1. Metastatic Melanoma Diagnostic Picture
Figure 2. Global Metastatic Melanoma Diagnostic Revenue Market Share by Type in 2021
Figure 3. BRAF Mutation
Figure 4. Circulating Tumor Cells (CTCs)
Figure 5. Immunohistochemistry
Figure 6. Others
Figure 7. Metastatic Melanoma Diagnostic Revenue Market Share by Application in 2021
Figure 8. Pathology Laboratories Picture
Figure 9. Hospitals Picture
Figure 10. Cancer Research Centres Picture
Figure 11. Others Picture
Figure 12. Global Metastatic Melanoma Diagnostic Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 13. Global Metastatic Melanoma Diagnostic Revenue and Forecast (2017-2028) & (USD Million)
Figure 14. Global Metastatic Melanoma Diagnostic Revenue Market Share by Region (2017-2028)
Figure 15. Global Metastatic Melanoma Diagnostic Revenue Market Share by Region in 2021
Figure 16. North America Metastatic Melanoma Diagnostic Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. Europe Metastatic Melanoma Diagnostic Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. Asia-Pacific Metastatic Melanoma Diagnostic Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. South America Metastatic Melanoma Diagnostic Revenue (USD Million) and Growth Rate (2017-2028)
Figure 20. Middle East and Africa Metastatic Melanoma Diagnostic Revenue (USD Million) and Growth Rate (2017-2028)
Figure 21. Metastatic Melanoma Diagnostic Market Drivers
Figure 22. Metastatic Melanoma Diagnostic Market Restraints
Figure 23. Metastatic Melanoma Diagnostic Market Trends
Figure 24. Myriad Genetics Recent Developments and Future Plans
Figure 25. Abbott Laboratories Recent Developments and Future Plans
Figure 26. Foundation Medicine Recent Developments and Future Plans
Figure 27. Pathway Genomics Corporation Recent Developments and Future Plans
Figure 28. Cancer Genetics Recent Developments and Future Plans
Figure 29. Castle Biosciences Recent Developments and Future Plans
Figure 30. NeoGenomics Recent Developments and Future Plans
Figure 31. Dermtech Recent Developments and Future Plans
Figure 32. Sysmex Inostics Recent Developments and Future Plans
Figure 33. Global Metastatic Melanoma Diagnostic Revenue Share by Players in 2021
Figure 34. Metastatic Melanoma Diagnostic Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 35. Global Top 3 Players Metastatic Melanoma Diagnostic Revenue Market Share in 2021
Figure 36. Global Top 10 Players Metastatic Melanoma Diagnostic Revenue Market Share in 2021
Figure 37. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 38. Global Metastatic Melanoma Diagnostic Revenue Share by Type in 2021
Figure 39. Global Metastatic Melanoma Diagnostic Market Share Forecast by Type (2023-2028)
Figure 40. Global Metastatic Melanoma Diagnostic Revenue Share by Application in 2021
Figure 41. Global Metastatic Melanoma Diagnostic Market Share Forecast by Application (2023-2028)
Figure 42. North America Metastatic Melanoma Diagnostic Sales Market Share by Type (2017-2028)
Figure 43. North America Metastatic Melanoma Diagnostic Sales Market Share by Application (2017-2028)
Figure 44. North America Metastatic Melanoma Diagnostic Revenue Market Share by Country (2017-2028)
Figure 45. United States Metastatic Melanoma Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 46. Canada Metastatic Melanoma Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. Mexico Metastatic Melanoma Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. Europe Metastatic Melanoma Diagnostic Sales Market Share by Type (2017-2028)
Figure 49. Europe Metastatic Melanoma Diagnostic Sales Market Share by Application (2017-2028)
Figure 50. Europe Metastatic Melanoma Diagnostic Revenue Market Share by Country (2017-2028)
Figure 51. Germany Metastatic Melanoma Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. France Metastatic Melanoma Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. United Kingdom Metastatic Melanoma Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Russia Metastatic Melanoma Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Italy Metastatic Melanoma Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Asia-Pacific Metastatic Melanoma Diagnostic Sales Market Share by Type (2017-2028)
Figure 57. Asia-Pacific Metastatic Melanoma Diagnostic Sales Market Share by Application (2017-2028)
Figure 58. Asia-Pacific Metastatic Melanoma Diagnostic Revenue Market Share by Region (2017-2028)
Figure 59. China Metastatic Melanoma Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Japan Metastatic Melanoma Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. South Korea Metastatic Melanoma Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. India Metastatic Melanoma Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Southeast Asia Metastatic Melanoma Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Australia Metastatic Melanoma Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. South America Metastatic Melanoma Diagnostic Sales Market Share by Type (2017-2028)
Figure 66. South America Metastatic Melanoma Diagnostic Sales Market Share by Application (2017-2028)
Figure 67. South America Metastatic Melanoma Diagnostic Revenue Market Share by Country (2017-2028)
Figure 68. Brazil Metastatic Melanoma Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Argentina Metastatic Melanoma Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Middle East and Africa Metastatic Melanoma Diagnostic Sales Market Share by Type (2017-2028)
Figure 71. Middle East and Africa Metastatic Melanoma Diagnostic Sales Market Share by Application (2017-2028)
Figure 72. Middle East and Africa Metastatic Melanoma Diagnostic Revenue Market Share by Country (2017-2028)
Figure 73. Turkey Metastatic Melanoma Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Saudi Arabia Metastatic Melanoma Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. UAE Metastatic Melanoma Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Methodology
Figure 77. Research Process and Data Source
Figure 1. Metastatic Melanoma Diagnostic Picture
Figure 2. Global Metastatic Melanoma Diagnostic Revenue Market Share by Type in 2021
Figure 3. BRAF Mutation
Figure 4. Circulating Tumor Cells (CTCs)
Figure 5. Immunohistochemistry
Figure 6. Others
Figure 7. Metastatic Melanoma Diagnostic Revenue Market Share by Application in 2021
Figure 8. Pathology Laboratories Picture
Figure 9. Hospitals Picture
Figure 10. Cancer Research Centres Picture
Figure 11. Others Picture
Figure 12. Global Metastatic Melanoma Diagnostic Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 13. Global Metastatic Melanoma Diagnostic Revenue and Forecast (2017-2028) & (USD Million)
Figure 14. Global Metastatic Melanoma Diagnostic Revenue Market Share by Region (2017-2028)
Figure 15. Global Metastatic Melanoma Diagnostic Revenue Market Share by Region in 2021
Figure 16. North America Metastatic Melanoma Diagnostic Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. Europe Metastatic Melanoma Diagnostic Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. Asia-Pacific Metastatic Melanoma Diagnostic Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. South America Metastatic Melanoma Diagnostic Revenue (USD Million) and Growth Rate (2017-2028)
Figure 20. Middle East and Africa Metastatic Melanoma Diagnostic Revenue (USD Million) and Growth Rate (2017-2028)
Figure 21. Metastatic Melanoma Diagnostic Market Drivers
Figure 22. Metastatic Melanoma Diagnostic Market Restraints
Figure 23. Metastatic Melanoma Diagnostic Market Trends
Figure 24. Myriad Genetics Recent Developments and Future Plans
Figure 25. Abbott Laboratories Recent Developments and Future Plans
Figure 26. Foundation Medicine Recent Developments and Future Plans
Figure 27. Pathway Genomics Corporation Recent Developments and Future Plans
Figure 28. Cancer Genetics Recent Developments and Future Plans
Figure 29. Castle Biosciences Recent Developments and Future Plans
Figure 30. NeoGenomics Recent Developments and Future Plans
Figure 31. Dermtech Recent Developments and Future Plans
Figure 32. Sysmex Inostics Recent Developments and Future Plans
Figure 33. Global Metastatic Melanoma Diagnostic Revenue Share by Players in 2021
Figure 34. Metastatic Melanoma Diagnostic Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 35. Global Top 3 Players Metastatic Melanoma Diagnostic Revenue Market Share in 2021
Figure 36. Global Top 10 Players Metastatic Melanoma Diagnostic Revenue Market Share in 2021
Figure 37. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 38. Global Metastatic Melanoma Diagnostic Revenue Share by Type in 2021
Figure 39. Global Metastatic Melanoma Diagnostic Market Share Forecast by Type (2023-2028)
Figure 40. Global Metastatic Melanoma Diagnostic Revenue Share by Application in 2021
Figure 41. Global Metastatic Melanoma Diagnostic Market Share Forecast by Application (2023-2028)
Figure 42. North America Metastatic Melanoma Diagnostic Sales Market Share by Type (2017-2028)
Figure 43. North America Metastatic Melanoma Diagnostic Sales Market Share by Application (2017-2028)
Figure 44. North America Metastatic Melanoma Diagnostic Revenue Market Share by Country (2017-2028)
Figure 45. United States Metastatic Melanoma Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 46. Canada Metastatic Melanoma Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. Mexico Metastatic Melanoma Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. Europe Metastatic Melanoma Diagnostic Sales Market Share by Type (2017-2028)
Figure 49. Europe Metastatic Melanoma Diagnostic Sales Market Share by Application (2017-2028)
Figure 50. Europe Metastatic Melanoma Diagnostic Revenue Market Share by Country (2017-2028)
Figure 51. Germany Metastatic Melanoma Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. France Metastatic Melanoma Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. United Kingdom Metastatic Melanoma Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Russia Metastatic Melanoma Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Italy Metastatic Melanoma Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Asia-Pacific Metastatic Melanoma Diagnostic Sales Market Share by Type (2017-2028)
Figure 57. Asia-Pacific Metastatic Melanoma Diagnostic Sales Market Share by Application (2017-2028)
Figure 58. Asia-Pacific Metastatic Melanoma Diagnostic Revenue Market Share by Region (2017-2028)
Figure 59. China Metastatic Melanoma Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Japan Metastatic Melanoma Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. South Korea Metastatic Melanoma Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. India Metastatic Melanoma Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Southeast Asia Metastatic Melanoma Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Australia Metastatic Melanoma Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. South America Metastatic Melanoma Diagnostic Sales Market Share by Type (2017-2028)
Figure 66. South America Metastatic Melanoma Diagnostic Sales Market Share by Application (2017-2028)
Figure 67. South America Metastatic Melanoma Diagnostic Revenue Market Share by Country (2017-2028)
Figure 68. Brazil Metastatic Melanoma Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Argentina Metastatic Melanoma Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Middle East and Africa Metastatic Melanoma Diagnostic Sales Market Share by Type (2017-2028)
Figure 71. Middle East and Africa Metastatic Melanoma Diagnostic Sales Market Share by Application (2017-2028)
Figure 72. Middle East and Africa Metastatic Melanoma Diagnostic Revenue Market Share by Country (2017-2028)
Figure 73. Turkey Metastatic Melanoma Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Saudi Arabia Metastatic Melanoma Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. UAE Metastatic Melanoma Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Methodology
Figure 77. Research Process and Data Source
